Kristina has spent 20+ years in drug development, 17 years at Bristol-Myers Squibb (BMS). She is currently an Early Development Project Leader supporting Immunology. Previously she was in Global Regulatory Strategy and Policy where she had been supporting immunology and fibrosis projects. Prior to joining Regulatory, she held roles of increasing responsibility in Drug Safety Evaluation and was the Therapy Area Head for Fibrotic and Metabolic Diseases in addition to being a project toxicologist. Before joining BMS she was a project toxicologist at Roche Palo Alto and Targeted Genetics.
During her career she’s supported multiple therapeutic areas including fibrosis, metabolic diseases, cardiovascular, immuno-oncology and neuroscience. She’s been actively involved or led efforts for IND/CTAs, global marketing applications (NDA/MAAs including ONGLYZA, KOMBIGLYZE, QTERN), life-cycle management and business development activities, and has authored numerous peer-reviewed publications.
Kristina received her PhD in Pharmacology and Toxicology from Duke University with a dissertation in neurodevelopmental toxicity of a pesticide. She is a Full Member of the American College of Toxicology and Society of Toxicology (SOT), and is a Diplomate of the American Board of Toxicology. Within SOT she's held multiple leaderships roles including Membership Committee, SIG-CG, Women in Toxicology (held each elected role across ~ 12 years), and Regulatory and Safety Evaluation Specialty Section (presidential chain 2020-2024).
In her free time Kristina enjoys traveling and expressing her artistic side with a business selling ceramics and beaded jewelry and teaching beadwork.